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Heparanase1
(HPA1), an endoglycosidase, specifically degrades the heparan sulfate side chain of heparan sulfate proteoglycans (HSPG) in the extracellular matrix or at the basement membrane [1, 2] , resulting in the destruction of the extracellular matrix or basement membrane and facilitation of cell movements. HPA1 also promotes angiogenesis in tumor tissues through the activation of vascular endothelial growth factor (VEGF) that binds to HSPG. Previous studies have revealed that HPA1 is overexpressed in most tumor tissues including liver cancer, which facilitates angiogenesis and tumor invasiveness, with a positive correlation between HPA1 expression levels and its effects [3, 4] . Currently, interference methods targeting HPA1 commonly used are HPA1 inhibitors and RNA interference (RNAi). Heparin is a complex polysaccharide that inhibits HPA1 activity [5] . Meanwhile, RNAi technology is widely used to inhibit target gene expression through a specific interaction between small interfering RNA (siRNA) and the target gene. RNAi or heparin alone is able to inhibit HPA1 www.cjcsysu.cn expression and its activity, however, both of them have some disadvantages respectively. RNAi alone cannot completely inhibit HPA1 expression and highdose RNAi is also associated with offtarget effects. Similarly, anticoagulant effect develops with highdose heparin. These shortcomings are likely to affect the antitumor effects of RNAi and heparin when applied alone. However, the effect of a combination of RNAi and heparin has not been extensively explored.
Hepatocellular carcinoma is one of the most common and malignant cancers. Hepa16, HcaP and HcaF are three mouse hepatocellular carcinoma cell lines with increasing metastatic ability [6, 7] . Studies have shown that the activity of HPA1 in the blood serum of patients with tumors increased, which is of clinical significance for an early diagnosis of tumor metastasis and prognosis [8] . Therefore, one of the main focuses on research of hepatocellular carcinoma is to study the function of HPA1 in tumorigenesis and progression, and to look for effective diagnostic markers and treatment for hepato cellular carcinoma by targeting HPA1. Our study thus aims to determine HPA1 expression levels in mouse hepatocellular carcinoma cell lines with different metastatic potential, and to investigate the effect of treatment with combination of HPA1 specific siRNA and heparin on tumor cell invasion.
HcaF and HcaP cells were kindly provided by the lab of glycobiology and glycoengineering at Dalian Medical University. Hepa16 cell was purchased from Chinese Academy of Medical Sciences; reverse transcription polymerase chain reaction (RTPCR) kit was purchased from TaKaRa Bio. Inc., Dalian. Primers were synthesized by TaKaRa Bio. Inc.. Lipofectamine 2000, Protein AAgarose affinity chromatography, and Trizol were purchased from Invitrogen Corporation. Fetal bovine serum (FBS), RPMI1640 and Dulbecco爷s modified Eagle爷s medium (DMEM) were purchased from GIBCO. siRNAs were synthesized by Shanghai Gene Pharma Co., Ltd. Rabbit antimouse HPA1 antibody, rabbit antimouse GAPDH antibody, and horseradish peroxidaseconjugated polyclonal goat antirabbit secondary antibody were purchased from Santa Cruz Biotechnology. Heparin was obtained from Tianjin Biochemical Pharmaceutical Co., Ltd. Transwell chambers were purchased from Corning Life Science. Matrigel was purchased from BD Biosciences.
HcaF and HcaP cells were cultured in RPMI1640 medium containing 10% FBS, while Hepa16 cells were cultured in DMEM containing 10% FBS. Cells were maintained at a 37益 incubator with 5% CO 2 and cells in logarithmic growth phase were used for experiments.
Two pairs of siRNA (siRNA1 and siRNA2), matching sequence domains of 334353 and 393411 of HPA1 mRNA sequence (NCBI access #: NM_152803.4), were designed using the Ambion siRNA software. Scrambled siRNA was also designed and used as a negative control. siRNAs were synthesized by Shanghai Gene Pharma Co., Ltd, and the specific siRNA sequences were as follows: siRNA1, 5'TCTCAAGTCAACCATGATATdTdT3' (forward), 5'ATATCATGGTTGACTTGAGAdTdT3' (reverse); siRNA2,5'CTCCAGGTGGAATGGCCCTdTdT3' (forward), 5'AGGGCCATTCCACCTGGAGdTdT3' (reverse).
HcaF cells were cultured in RPMI1640 medium containing 10% FBS to reach 60% 80% confluence 24 h before siRNA treatment. siRNA1 and siRNA2 were diluted using serumfree RPMI1640 medium to final concentrations of 10 nmol/L, 30 nmol/L, and 100 nmol/L, respectively. Cells were then transfected with siRNA through Lipofectamine 2000 according to manufacturer爷s instruction. Cells were harvested 48 h after transfection for RTPCR analysis and cell culture supernatants were collected for ELISA assay.
HcaF cells were seeded to 6well plates at a density of 3 伊 10 5 cells/well 24 h prior to treatment. The experiment contains 6 groups of cells in triplicates. The siRNA2 alone group was treated with 10 nmol/L siRNA2 for 48 h. The combination of siRNA2 and heparin group was treated with 10 nmol/L siRNA2 for 48 h, followed by additional incubation with 25 U of heparin for 6 h. The Heparin alone group was incubated with 25 U heparin for 6 h. The scramble siRNA group was treated with scramble siRNA for 48 h. The combination of scramble siRNA and heparin group was treated with scramble siRNA for 48 h, followed by additional incubation with 25 U of heparin for 6 h. Untreated HcaF cells were used as a control. Cells in each group were harvested for RTPCR and the cell culture supernatants were collected for ELISA assay.
The sequences of HPA1 primers were: F1, 5'CTTTGGTCTAAATGCGTTACTAC3', and R1, 5'CTG CCTCATCACGACTTCTATG3'. The sequence of GAPDH primers were: F2, 5'CCAGTATGACTCCACTCACG3', and R2, 5'GGATGATGTTCTGGGCAGCC3'. After total mRNA was extracted using Trizol reagent, RTPCR was performed as described in manufacturer爷s instruction. GAPDH served as an internal reference. PCR products were separated in 1% agarose gel. The bands were scanned and relative HPA1 mRNA expression levels were determined by comparing with the expression of GAPDH.
The same amount (2 伊 10 6 ) of HcaF, HcaP, and Hepa16 cells were cultured with 15 mL medium supplemented with 10% FBS for 48 h in 10cm dishes. Then the cell culture supernatants were collected and purified by Protein A affinity chromatography to remove IgG. The protein contents in the supernatant extract were precipitated with trichloroacetic acid (TCA)acetone and dissolved in 100 滋 L loading buffer, then the concentration of protein was measured by Bradford protein assay. A total of 50 滋 g of protein were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE) and subjected to Western blot analysis. The primary antibody was rabbit antimouse polyclonal antibody against HPA1 (1: 200). The second antibody was horseradish peroxidase conjugated goat antirabbit polyclonal antibody (1:5000). The immunoreactive proteins were visualized by enhanced chemiluminescence (ECL) kit for Western blot detection. Meanwhile, total proteins were prepared from different hepatocellular carcinoma cell lines and concentration of protein was determined by Bradford protein assay. A total of 50 滋 g of total protein were separated by SDSPAGE. The internal control, GAPDH, was analyzed using Western blot analysis. The primary antibody was GAPDH rabbit antimouse polyclonal antibody (1:100). The secondary antibody was horseradish peroxidaseconjugated goat antirabbit polyclonal antibody (1:8000). The immunoreactive total proteins were visualized by enhanced chemiluminescence (ECL) kit. Glyceraldehyde 3phosphate dehydrogenase (GAPDH) was used as internal control and, after analysis of gel imaging system, relative expression levels of secreted HPA1 were determined by comparing with the expression of GAPDH.
The same amount (50 滋 L) of culture supernatants with IgG removed were obtained from culture mediums of HcaF, HcaP, Hepa16 cells, and HcaF cells treated with different concentrations of siRNA1 or siRNA2, and the protein contents in the supernatant extract were measured by ELISA assay. HcaF cells were divided into 6 groups according to different treatment conditions as follows: siRNA2 (10 nmol/L), siRNA2 (10 nmol/L) plus heparin (25 U), heparin (25 U), scramble siRNA, scramble siRNA plus heparin (25 U), and untreated control. Five replicates were set for each group. The primary antibody was rabbit antimouse polyclonal antibody HPA1 (1:2000) and the second antibody was horseradish peroxidaseconjugated goat antirabbit polyclonal antibody
(1:10000). The absorbance was determined using a microplate reader at 450 nm and the amount of secreted HPA1 was presented as the mean value of absorbance. six groups of HcaF cells described above were cultured in serumfree RPMI1640 medium for 24 h. Cells were re suspended in serumfree medium containing 0.1% bovine serum albumin (BSA) at a final concentration of 3 伊 10 5 cells/mL. A total of 25 U heparin was added into heparin treated group, siRNA2 (10 nmol/L) plus heparin treated group and scramble siRNA plus heparin treated group. A total of 50 滋 g of matrigel was added into each transwell chamber, One hundred 滋 L of cell suspension was added into the upper chambers, and 500 滋 L culture medium containing 15% FBS was added into the lower chambers. After the cells were cultured in normal condition for 18 h, the polycarbonate membrane was stained by WrightGiemsa and examined under microscopy. Five high power fields (伊 400) of cells were counted and the mean value was calculated as the final result.
All data were analyzed using SPSS 12.0 software. The results were presented as mean 依 standard deviation (SD) and subjected to test analysis. A value of < 0.05 was considered as statistically different.
RTPCR results showed that the expression levels of HPA1 mRNA in HcaF and HcaP cells were 1.21 依 0.02 www.cjcsysu.cn and 0.25 依 0.01, respectively, with a significant difference between the two groups ( < 0.001). No HPA1 mRNA expression was detected in Hepa16 cells (Figure 1 ). These results indicate that HPA1 mRNA expression levels are positively correlated with the metastatic potentials of mouse hepatocellular carcinoma cells.
Figure 1
Detection of HPA鄄 1 mRNA by RT鄄 PCR in Hca鄄 F, Hca鄄 P, and Hepa1鄄 6 cells Total RNA was isolated from the Hca鄄 F, Hca鄄 P, and Hepa1鄄 6 cells. After reverse transcription, the expression levels of HPA鄄 1 mRNA were analyzed by PCR followed by agarose gel electrophoresis of the PCR products and ethidium bromide staining. GAPDH mRNA levels were used as a control. Lane M, marker; Lane 1, Hca鄄 F cells; Lane 2, Hca鄄 P cells; Lane 3, Hepa1鄄 6 cells.
Western blot analysis showed that the secreted HPA1 content in culture supernatants of HcaF cells (1.34 依 0.02) was significantly higher than that of HcaP cells (0.60 依 0.01) ( < 0.001), while no secreted HPA1 was detected in that of Hepa16 cells (Figure 2A) . ELISA results also showed that the secreted HPA1 in culture supernatants of HcaF cells (0.86 依 0.03) was higher than that of HcaP cells (0.21 依 0.02) ( < 0.001) ( Figure 2B ). Our results therefore suggest that secreted HPA1 levels are positively correlated with the metastatic potentials of mouse hepatocarcinoma cell. After HcaF cells were treated with siRNA1 at final concentrations of 10 nmol/L, 30 nmol/L, and 100 nmol/L, the expression levels of HPA1 mRNA were 0.64 依 0.02, 0.51 依 0.02, and 0.33 依 0.02, respectively. After HcaF cells were treated with siRNA2 at final concentrations of 10 nmol/L, 30 nmol/L, and 100 nmol/L, the expression levels of HPA1 mRNA were 0.32 依 0.01, 0.30 依 0.01, and 0.20 依 0.02, respectively (Figure 3) . Therefore, the effect of siRNA2 was significantly greater than that of siRNA1 ( = 0.002, 0.0008, and 0.008, respectively). siRNA2 at the concentration of 100 nmol/L worked better than did siRNA2 at the concentration of 30 nmol/L and 10 nmol/L ( = 0.003 and 0.002), while there was no statistical difference between the 30 nmol/L and 10 nmol/L treated groups ( = 0.070). HPA1 mRNA expression levels of untreated and scramble siRNA treated HcaF cells were 0.88 ± 0.01 and 0.87 ± 0.01, which was not significantly different from each other ( = 0.230). These results suggest that HPA1 specific siRNA1 and siRNA2 can effectively inhibit the expression of HPA1 mRNA in HcaF cells, and siRNA2 is more effective. To avoid potential offtarget effect of siRNA treatment, we used siRNA2 at a final concentration of 10 nmol/L for subsequent experiments. RTPCR results showed that the expression level of HPA1 mRNA in siRNA2 (10 nmol/L) treated group was 0.30 + 0.01, which was similar to that in siRNA2 (10 nmol/L) plus heparin (25 U) treated group (0.31 依 0.03) ( = 0.480). The HPA1 mRNA expression level in untreated normal HcaF cells was 0.92 依 0.02, which was significantly higher than that in siRNA2 (10 nmol/L) treated cells ( < 0.001). The expression levels of HPA1 mRNA in scramble siRNA, heparin (25 U), and scramble siRNA plus heparin (25 U) treated cells were 0.91 ± 0.01, 0.94 依 0.02, and 0.95 依 0.03, respectively, which were not significantly different from that in the untreated normal HcaF cells ( = 0.422, 0.225, and 0.188, respectively) (Figure 6 ). These results suggest that siRNA2 inhibits the expression of HPA1 mRNA, while heparin does not. Metastasis is a leading cause of cancer death. Cell adhesion, migration, extracellular matrix degradation and angiogenesis are key factors for tumor metastasis [2] . Studies have demonstrated that HPA1 plays an important role in tumor angiogenesis and cancer cell invasion, and thus it has become a new therapeutic target to inhibit tumor metastasis.
It has been shown that HPA1 specific siRNAs can prevent mouse B16BL6 melanoma cells from metastasizing to liver and lung, and inhibit angiogenesis in tumor tissues. In addition, B16BL6 cells which are capable of secreting HPA1 are prone to metastasize and promote angiogenesis, which can be inhibited by downregulating the secretion of HPA1 using siRNA [8] . It is generally accepted that secreted HPA1 enhances cancer cells migration across basement membrane and extracellular matrix, thus facilitating cancer metastasis. However, most of secreted HPA1 in these studies comes from exogenous expression through DNA recombination and it is difficult to find a cell model with endogenous HPA1 secretion. In the present study, we found that the expression and secretion of HPA1 in mouse hepatocellular carcinoma cell lines HcaP and HcaF increase as their metastatic potential enhances, and therefore these cell lines provide a good model to study the function of secreted HPA1 in cancer metastasis.
Two pairs of HPA1 specific siRNA were used in this study. Since the effect of siRNA2 is much better than siRNA1, we chose siRNA2 in subsequence experiments. We found that there is no significant difference between the 10 nmol/L and 30 nmol/L siRNA2 treated groups. Even though 100 nmol/L siRNA2 is more effective, it leads to offtarget effect, meanwhile the expression of endogenous GAPDH is also reduced (Data not shown). The reason for this nonspecific interference needs further investigation. Therefore, we used siRNA2 at a final concentration of 10 nmol/L, which inhibits 64% of the expression of HPA1. Since the remaining 36% of HPA might still exert its function, we explored if other methods can be used at the same time to inhibit HPA1 activity. Currently, heparin is another important inhibitor of HPA1 activity. The structure of heparin is similar to the heparan sulfate side stain of heparan sulfate proteoglycans, a substrate for HPA1. Therefore heparin acts as a competitive inhibitor of HPA1. It has been confirmed in animal models that heparin inhibits tumor growth , metastasis and angiogenesis through HPA1 [5] . However, it is unclear if the anticoagulant activity of heparin has any influences on its antitumor activity, which requires further basic and clinical research. Some studies reported that large doses of heparin may interfere with its clinical application to inhibit tumor metastasis because of the anticoagulan t effect. Therefore, it is important to choose an appropriate dose of heparin that can inhibit HPA1 activity with less anticoagulant activity. To determine the appropriate dose of heparin, we treated HcaF cells with different doses of heparin and found that the minimum dose of heparin required to decrease the invasion ability of HcaF cells in matrigel is 25 U (results not shown). Therefore, we used heparin at a concentration of 25 U in this study to inhibit HPA1 activity.
Our study revealed that the combination of HPA1 specific siRNA and low doses of heparin can inhibit HcaF cell invasion more efficiently than does either of them. However, further in vivo experiments are needed to elucidate the effect of the combined treatment on tumor metastasis and angiogenesis. Nevertheless, the combination of HPA1 specific siRNA and heparin provides a novel idea to treat tumor metastasis and angiogenesis through inhibiting HPA1 activity.
